伊甸生醫新執行長李世雄博士上任

Eden Biologics, Inc.

Eden Biologics, Inc.

總部位於台灣新竹的生技公司伊甸生醫宣布任命李世雄博士(Dr. Steve Lee)為新任執行長與董事會成員。李博士對於生物製劑研究、生物製程開發、技術營運、業務發展、策略規劃和商業製造方面,有30多年傑出經驗。李博士曾帶領美國和亞洲的生技新創與大型生物製藥集團轉型為高績效組織。

新竹, 台灣, September 1, 2021 /EINPresswire.com/ — 總部位於台灣新竹的前瞻生技公司伊甸生醫,於 9 月 1日宣布任命在生技領域極具經驗與創業領導魄力的成功經理人李世雄博士(Dr. Steve Lee),為新任執行長與董事會成員,即刻生效。李博士是一位備受尊敬的執行長和業界領袖,在規範嚴謹的環境和新興市場中,對於生物製劑研究、生物製程開發、技術營運、業務發展、策略規劃和商業製造方面,有30 多年傑出經驗。李博士曾帶領美國和亞洲的生技新創與大型生物製藥集團轉型為高績效組織。

伊甸生醫董事長黃瑞瑨表示:「我們竭誠歡迎李博士成為伊甸生醫新執行長。他是一位公認的科學領袖,在伊甸處於加速成長及創新之際,我很高興李博士接任我們的新執行長。李博士在策略領導和高效營運執行方面表現出色,可以繼續推動伊甸正蓬勃發展的生物製劑開發,同時高度專注於我們的願景,即為所有需要的患者提供價格合理的優質生物藥品。他在治療性生物製劑和新型疫苗製造方面的專業經驗擴大了公司的經營策略,我非常興奮他來帶領伊甸並把握所有未來的全球市場機會。」

作為美國BioGENEXUS, LLC的創辦人暨前執行長,李博士開發顛覆性創新和突破性製造技術平台,同時提供全球生物技術諮詢服務。而今,李博士將其豐富業界經驗、強大領導力和熱情帶進伊甸生醫,以期在亞洲及美國擴大伊甸創新與具成本效益的生物製劑開發平台和商業製造聯盟。創辦BioGENEXUS之前,李博士是印度製藥公司 Dr. Reddy's Labs (DRL) Biologics 生物製劑技術部門全球負責人和新加坡分公司執行長。該公司是亞洲領先生物相似藥廠之一,李博士負責四款商業生物製劑生產,並協助六款開發中之生物相似藥。在加入DRL之前,李博士是中國綠葉製藥集團生物製劑業務的全球負責人,該集團收購了新加坡政府創立的生技公司 A-Bio Pharma,李博士當時為該公司執行長。

回亞洲服務之前,李博士是美商必治妥施貴寶公司(BMS)的副總裁兼製程開發與製造部總經理,負責領導紐約雪城的製造部門和製程開發團隊,開發並推出廣泛的蛋白質療法和後期開發生物製劑。在嚴格的時間限制下,李博士為 BMS 生物製劑特許經營成立了一個高績效團隊以開發永續基礎設施,並獲得 FDA 批准推出首款BMS 自行開發的自體免疫生物製劑 Orencia®。他亦曾擔任生物製劑開發卓越中心負責人,帶領跨部門團隊在麻州建立自有大型細胞培養設備(6座20,000升生物反應器),使BMS有效擴展版圖並成為今日腫瘤免疫學巨頭。加入 BMS 之前,李博士還曾在兩家全球製藥公司工作:默克和羅氏藥廠之美國分公司。李博士在紐澤西州的兩個默克實驗室擔任過多個職位,負責開發各種疫苗和生物衍生療法製程,包括推出抗真菌劑 Cancidas®;而於賓州的默克製造部門,他建立並帶領一個整合無菌製程、工程和技術服務團隊,以支持所有商業生物製劑並推出新型疫苗。

李博士為台灣大學農業化學學士,密西根大學化學工程碩士,麻省理工學院生化工程博士。

關於伊甸生醫:
伊甸生醫成立於2012年,在以董事長暨執行長黃瑞瑨(亦為凱鵬華盈國際創投大中華區合夥人)為首的全新管理團隊領導轉型下,持續專注於三個生物製藥領域:1)為客戶提供合約製造代工服務(從細胞株開發到商業量產,並提供法規諮詢及送件服務);2)開發自有生物相似藥產品線;3)生物製劑新藥合作與授權。
欲知詳情,歡迎e-mail至 partner@edenbiologics.com

Yen Hsieh
Eden Biologics, Inc.
+886 3 658 3899
email us here
Visit us on social media:
LinkedIn


Source: EIN Presswire

Eden Biologics Introduces New Chief Executive Officer, Dr. Steve Lee

Eden Biologics, Inc.

Eden Biologics, Inc.

Eden Biologics, a leading global biotechnology company based in Taiwan, announced the appointment of Dr. Steve Lee as the new CEO and Director of the Board.

HSINCHU, TAIWAN, September 1, 2021 /EINPresswire.com/ — Eden Biologics, Inc., a leading global biotechnology company based in Hsinchu, Taiwan, announced on September 1st, the appointment of Dr. Steve Lee, an accomplished biotech executive with broad experience and entrepreneurial leadership, as the new CEO and Director of the Board, effective immediately. Dr. Steve Lee is a highly respected CEO and global business leader with a distinguished track record in biologics research, bioprocess development, technical operations, business development, strategic planning, and commercial manufacturing in a highly regulated environment and emerging markets for over 30 years. Specifically, Dr. Lee has led changes in transforming companies into high-performance organizations in biotech startups and large biopharmaceutical groups in the United States and Asia.

James Huang, Chairman of the Board of Eden Biologics: “We are very excited to welcome Dr. Steve Lee as Eden Biologics’ new Chief Executive Officer. He is a well-recognized, proven scientific leader at a time when Eden is in excellent position to accelerate growth and innovation and I am very pleased to welcome Dr. Lee as our new CEO. Dr. Lee has excelled at strategic leadership and efficient operational execution throughout his career and is well-positioned to continue to enhance Eden’s thriving biologics development while maintaining a hyper focus on our vision to make affordable, high-quality biological medicines for all patients in need. His invaluable commercial expertise in the manufacturing of both therapeutic biologics and novel vaccines amplifies the company’s strategic direction and I’m ecstatic to have him lead Eden and take advantage of all future global market opportunities.”

Previously the CEO and Founder of BioGENEXUS, LLC, Dr. Lee developed disruptive innovation and breakthrough manufacturing technology platforms while providing biotech consulting services globally. Now he brings his extensive biotech industry experience, strong leadership and passion to Eden Biologics with hopes of expanding Eden’s innovative, cost-effective biologics development platform and commercial manufacturing alliances in both Asia and the US. Before founding his own firm, Dr. Lee was the Global Head, Biologics Technical Operations and CEO of Singapore Operations for Dr. Reddy’s Labs (DRL) Biologics, one of Asia’s leading biosimilar developers and was responsible for overseeing the manufacturing four commercial biologics while supporting six biosimilars in development. Before Dr. Reddy’s Labs, Dr. Lee was the Global Head, Biologics Business of Luye Pharma Group, a China-based pharmaceutical company, which acquired A-Bio Pharma in Singapore, a pioneering biotech company founded by Singapore government, where he served as CEO.

Prior to his return to Asia, Dr. Lee was Vice-President and General Manager, Process Development and Biologics Manufacturing, Bristol-Myers Squibb Company (BMS) where he was responsible for leading the Syracuse, New York Manufacturing and Process Development groups, developing and launching a wide range of protein therapeutics and late-stage development biologics. Most impressively, under severe time constraints, Dr. Lee established a high-performance team to develop sustainable infrastructure for the BMS biologics franchise and obtained FDA approval to launch the very first BMS internally developed biologic, Orencia® for autoimmune diseases. He also served as the Head of Biologics Development Center of Excellence and led a cross functional team to build its own large-scale commercial Cell Culture Manufacturing Facility (6×20,000L bioreactors) in Devens, MA, which enabled BMS to expand effectively as the immuno-oncology giant today. Prior to joining BMS, Dr. Lee also worked for two global pharmaceutical companies: Merck & Co., Inc. and Hoffmann-La Roche, Inc., both located in the US. At Merck, Dr. Lee held several positions of increasing responsibilities at both Merck Research Laboratories in Rahway, NJ, where he developed various bioprocesses for vaccines and biologically derived therapeutics including launching antifungal agent, Cancidas®; and Merck Manufacturing Division in West Point, PA, where he built and led an integrated sterile process, engineering and technical services group to support all commercial biologics and introduced novel vaccines.

Dr. Lee received his Ph.D. in Biochemical Engineering from the Massachusetts Institute of Technology (MIT); M.S. in Chemical Engineering from The University of Michigan; B.S. in Agricultural Chemistry from National University of Taiwan.

About Eden Biologics, Inc.
Eden Biologics is a biopharmaceutical company established in 2012 and after a transformation under new executive leadership led by James Huang, Chairman and CEO (also Managing Director of KPCB China), Eden continues to focus on three biotech sectors: 1) Accelerating the development programs for clients through the provision of Contract Development and Manufacturing Services (from cell line development to commercial manufacturing with regulatory filing support; 2) Developing a Proprietary Biosimilar Pipeline; and 3) Collaborating & Licensing of New and Innovative Biologics.
For more information, please contact us at partner@edenbiologics.com

Yen Hsieh
Eden Biologics, Inc.
+886 3658-3899
email us here
Visit us on social media:
LinkedIn


Source: EIN Presswire

Brian Dean Abramson, Esq., LL.M. Announces Second Edition of Legal Treatise "Vaccine, Vaccination, and Immunization Law"

LOS ANGELES, CA, UNITED STATES, August 31, 2021 /EINPresswire.com/ — I am pleased to announce the forthcoming publication of the second print edition of my legal treatise, "Vaccine, Vaccination, and Immunization Law," coauthored with Dorit Reiss, Peter O. Safir, and Jay Thomas. Publication is anticipated between late 2021 and early 2022 releasing in the United States, and it is made possible by an agreement between Bloomberg Law, as owner and publisher of the electronic version, and the American Health Law Association as publisher of the print volume.

With vaccine law rising sharply in importance over the course of the pandemic, it is timely and useful to introduce a second edition of this treatise, with numerous areas of updated and expanded content.

This work represents a massive expansion over the first print edition, with updates throughout, including content on COVID-19 vaccine development and mandates. The second edition will also contain entirely new chapters on:

¤ Employer/employee vaccination mandates, incentivization, facilitation, and promotion efforts;
¤ International and comparative vaccine law, including profiles of vaccine laws of selected countries
¤ Legal issues regarding anti-vaccine activism and responses

Other new materials include new or greatly expanded coverage of topics such as FDA Emergency Use Authorization, the Countermeasures Injury Compensation Program, applicability of Worker's Compensation for alleged vaccine injuries, OSHA standards and requirements, rights of minors seeking vaccination without parental consent, forced vaccination concerns, vaccination mandates for animals, and pandemic and bioterrorism response. I hope that everyone seeking information in this field will enjoy this volume and find it useful.

————–

Professor Brian Dean Abramson, Esq., LL.M. is a leading expert on vaccine law, having completed teaching the Vaccine Law course for the Florida International University College of Law, and having previously served as a law clerk to a judge of the United States Court of Appeals for the Federal Circuit, reviewing appeals of both vaccine injury claims and vaccine patent claims.

He published the first edition of the legal treatise, "Vaccine, Vaccination, and Immunization Law," in 2018, overcoming doubts as to whether there was sufficient interest to support a comprehensive legal treatise in this field. In 2021 he established Vaccination Program Counsel to advise individuals, organizations, and entities on matters of vaccine law, including legally compliant vaccination policies and procedures.

His vaccine law expertise has recently been quoted by Reuters, Bloomberg Law, the L.A. Times, Il Sussidiario, the Epoch Times, and The Conversation, and his writings have been cited in numerous academic publications.

Aurora DeRose
Boundless Media Inc.
+1 951-870-0099
email us here


Source: EIN Presswire

Lean Six Sigma makes landfall in the Caribbean

Albanesa Ymaya,  CEO of Ymaya Lean Academy, Dominican Republic

Albanesa Ymaya, CEO of Ymaya Lean Academy, Dominican Republic

Lean Six Sigma training  at Ymaya Lean Lean Academy,  Dominican Republic

The first Lean Academy in the Caribbean region

Lean Training with Ymaya Lean Academy, República Dominicana

Lean Training with Ymaya Lean Academy, Dominica Republic

República Dominicana es la primera en beneficiarse de la mejora empresarial utilizando Lean y Six Sigma

We are proud to be the #1 provider of Lean and Six Sigma training in the Caribbean region. Our training with the Microport CRM team in the Dominican Republic is an exciting new development for us.”

— Albanesa Ymaya, President and CEO Ymaya Lean Academy Inc.

CAMBRIDGE, UNITED KINGDOM, August 31, 2021 /EINPresswire.com/ — The Dominican Republic has become the first Caribbean country to embrace the business improvement methodologies of Lean and Six Sigma. The Ymaya Lean Academy, a partner of the International Lean Six Sigma Institute, ILSSI, has been training employees at the Microport CRM medical device manufacturing facility in Santo Domingo, República Dominicana. Albanesa Ymaya, President and CEO of Ymaya Lean Academy Inc. said '‘We are proud to be the #1 provider of Lean Production and Lean Six Sigma training in the Caribbean region. Our training programme with the Microport team in the Dominican Republic is an exciting new development for us’. Microport CRM specialise in the design and production of medical devices for Cardiac Rhythm Management.
The initial training comprises of 15 employees in the principles and tools and Lean and Six Sigma for the certification called 'Lean Six Sigma Yellow Belt' which is accredited by ILSSI, Cambridge, UK. The goal will be to train as many employees as possible over 2021 and 2022.
Ms. Ymaya was trained and gained her experience at the Toyota plant in Kentucky, Georgetown, USA as well as in other international companies. She has more than 18 years experience in the field, teaching and implementing Lean Manufacturing tools and strategies.
Ymaya Lean Academy puts on regular workshops and presents at conferences around the Caribbean as well as in Miami, Florida USA.

Juliane Haan
ILSSI.org
+44 1913755711
juliane@ilssi.org
Visit us on social media:
Facebook
Twitter
LinkedIn


Source: EIN Presswire

Facebook Strengthens Advertisement Policies Regarding Telehealth

Edward Kafterian, CEO Orbit Health Telepsychiatry

Edward Kafterian, CEO Orbit Health Telepsychiatry

Orbit Health Telepsychiatry Logo

Orbit Health Telepsychiatry

New policy requires pre-approval and certification that telehealth providers and online pharmacies are legitimate – by Amanda Tjan

Facebook can be very useful to allow reputable companies to educate the public and provide high-quality medical information.”

— Dr. Edward Kaftarian, CEO, Orbit Health

CALABASAS, CALIFORNIA, UNITED STATES, August 31, 2021 /EINPresswire.com/ — Facebook is not only a longstanding social media platform but is also widely used to promote products and services to a mass audience. As telemedicine continues to penetrate the healthcare industry, it is not surprising that pharmaceutical companies use Facebook as a means of advertising. In 2019, pharmaceutical companies spent over $1 billion on Facebook ads alone. While the proliferation of telehealth poses new challenges for the multibillion-dollar company, Facebook is strengthening its advertisement policies centered around telemedicine.

In Facebook’s existing policy, online pharmacies are required to undergo a certification process before advertising on the platform. In addition, the company prohibits the sale or trading of all prescription drugs. Facebook also bans ads that advocate or promote the consumption of illegal substances and unsafe supplements. Ads promoting drug-related paraphernalia are also prohibited.

Facebook’s new policy, effective August 25th, 2021, will require pre-approval for telehealth providers, online pharmacies, and pharmaceutical manufacturers using LegitScript, a third-party health regulation service. LegitScript combines data to ensure that companies are operating safely and legally. Only certified advertisers that fall into one of these three categories will be allowed to promote prescription drugs on the platform. Advertisements may not promote prescription drugs without prior written permission. In addition, Facebook maintains that ads cannot target minors and will only be available in the United States, Canada, and New Zealand.

Doctor Edward Kaftarian, CEO of telepsychiatry provider Orbit Health and telehealth training provider Orbit University, notes that LegitScript certification is also required for advertising similar services on Google. According to Dr. Kaftarian, Orbit Health sees LegitScript as a marker of quality that recognizes Orbit Health and Orbit University for their quality education and public outreach about telepsychiatry and telemental health services. “LegitScript now certifies telehealth providers,” says Dr. Kaftarian, “which will be needed if providers wish to promote their services to new customers.”

Orbit Health has used Facebook ads in the past to increase awareness among potential clients, but Dr. Kaftarian cautions that first-time users might be overwhelmed by the sheer number of options when it comes to scheduling ads anywhere from a few times a day to several times a week, plus choosing the locations and age brackets of consumers to target.

In Facebook’s announcement of the new policy, the company states that the purpose of strengthening its regulation of health advertisements stems from the intention of prohibiting illegal and unsafe substances. In 2018, Facebook cracked down on the sale of illicit drugs on the platform as a response to the growing opioid crisis. In 2017, there were an estimated 30,000 deaths due to overdose from opioids. Many of these drugs were bought online from social media platforms like Facebook.

Since then, Facebook has banned searches for words like “fentanyl” and “Xanax” to make it significantly harder for buyers to connect with sellers. In addition, Facebook has since added a feature that prompts users to the Substance Abuse & Mental Health Services Administration helpline when they use the site to search for illicit drugs.

While this is a step forward, targeted advertising still raises the question about privacy for consumers. In the 2016 lawsuit filed against Facebook, the plaintiffs claimed that the company invaded users’ privacy by tracking their visits to health-related websites. The privacy suit was later dismissed as internet searches are not deemed to be sensitive medical information and users agree to Facebook’s terms of service when creating an account. In addition, Facebook is not necessarily obligated to conceal the health information of its users as the Health Insurance Portability and Accountability Act (HIPAA) only applies to entities that directly deal with patient information.

Facebook recognizes that businesses in the medical industry want to raise awareness for pharmaceuticals and other health-related treatments. However, Facebook is also aware that the company must change its policies in order to adhere to the changing landscape of digital marketing. Doctor Kaftarian of Orbit Health recognizes that Facebook ads can be very useful to allow reputable companies to educate the public and provide high-quality medical information. “Facebook is a communication channel that allows companies to promote their brand to new and existing customers,” he says. Meanwhile, Facebook’s paid ads “can be helpful in increasing traffic, boosting retention, and expanding customer bases for existing Facebook pages.”

“Facebook advertising is a great way for small businesses to reach out to their customers and expand their reach,” concludes Dr. Kaftarian. This latest move by Facebook to require pre-approval for ads from telehealth providers and others using LegitScript is seen as a positive step toward enhancing public trust and confidence in healthcare information while cracking down on the sale of illicit drugs and misinformation when it comes to vital issues of public health.

Edward Kaftarian
Orbit Health
+1 844-672-4863
email us here
Visit us on social media:
Facebook
LinkedIn


Source: EIN Presswire

The Sales Control Plan Sets Standard for Sales Enablement

SalesPulse Illustration from Sales Control Plan Mangement

Accurate Training Trends and Efficiency Ratings from CRM

The sales control plan management platform is the solution for all B2B selling challenges.

Sales leaders usually hire to solve talent problems, and choose a brand of CRM to solve process problems. Two of the biggest mistakes made when managing a sales force.”

— Edward Henry

TORONTO, ONTARIO, CANADA, August 31, 2021 /EINPresswire.com/ — Imagine if you were able to see exactly where every opportunity is at in your pipeline. We have experienced those long-winded sales stories that still did not add up to a closed sale, or even determined what needed to be closed. Sales managers are in the dark when it comes to seeing where the opportunities are in the organization’s pipeline. This has been the reason for most of the sales waste that many companies struggle to identify.

As a leader we want those around us to succeed. It reflects well on our own efforts, but more importantly, on the organization. Sales Training is an excellent way of building relationships and supporting your team with all the necessary resources and tools that they require to succeed. You can easily create goodwill while simultaneously creating accountability amongst your team.

Sales Control Plan Management is a management and training resource that provides sales leaders, and the salesforce with everything they need to manage, train, onboard, and reference. It is the ultimate resource for sales intelligence. It is time to make real time solutions in real time.

SALES CONTROL PLAN MANAGEMENT

Training & Adoption

As the world changes around us, so has the way we learn and expand our skills. Sales Control Plan Management’s sales waste assessment identifies the sales waste and sales operation deficiencies in the sales organization. The results of the assessment provide the accurate roadmap to achieve highest standard for sales training and CRM adoption success.

Sales Control Plan

There are so many elements to manage when it comes to supervising a sales force. Sales Control Plan allows you to work with transparent metrics that help you to clearly see everything in your entire pipeline. You know exactly where to spend you time and resources for optimum sales management success. After implementation of baseline metrics, Sales Control Plan Management will provide the workflow automation that ensures your sales reps do not miss any opportunities.

There has never been a better management system that integrates with all brands of CRM to provide the highest level of accountability and sales intelligence throughout the entire sales force.

There is no more training on random selling methodologies or skill development. Sales Control Plan provides accurate training metrics which are accessed from actual CRM activity. Companies will eliminate massive training waste by training specifically in the area where the sales rep or sales force is struggling. Sales Control Plan solves every organization’s most costly selling challenges.

Benefits of Sales Control Plan Management

• Improved Customer Engagement
• Reduced Sales Waste
• Eliminate opportunities from going COLD!
• Sales Force Accountability – Management Accountability – Customer Accountability
• No more missed follow up calls
• No more missed deadlines on sales deliverables
• No more inactivity
• Complete pipeline visibility
• Simple onboarding of new hires saving money on training and resources.
• Progressive evaluation and sales analytics that produce accurate training scope based on CRM and selling practices.
• Real Time is REAL TIME
• CRM integration to make sure that learning requirements are triggered based on CRM performance metrics.
• Reduce and eliminates false reporting in CRM.
• Triggered emails specific to the customers sales stage, and engagement to communicate relevant requests, or notices where the sales representative has lost engagement due to inactivity or missed follow up.

Edward David Henry
Edward Henry Company
+1 647-725-7575
email us here


Source: EIN Presswire

Cancer Action Coalition of Virginia (CACV) to Hosts Virginia Cancer Conference "CEU's Offered"

CACV Conference Flyer

Cancer Action Coalition of Virginia (CACV) to Hosts Virginia Cancer Conference, "CEU's Offered"

Joining Together for a Virginia Without Cancer”

— CACV

RICHMOND, VA, UNITED STATES, August 31, 2021 /EINPresswire.com/ — The Cancer Action Coalition of Virginia (CACV) is hosting the Virtual Virginia Cancer Conference in September.

In 2021, over 46,000 Virginians will be diagnosed with cancer. The goal of the Virginia Cancer Conference is to provide education and training to stakeholders in the local cancer community to meet the multifaceted needs of persons living with cancer.

The virtual event will be held on three days, September 15, 22, and 29, from 9:30, am – 12:30 pm daily. Conference topics include COVID-19 Impact on Cancer Screening and Treatment; Health Equity and Cancer; LGBTQ Individuals and Cancer; Cancer Prevention and Screening; and much more.

Through live presentations, panel discussions, breakout rooms, and networking opportunities, the conference offers healthcare professionals, survivors, caregivers, and the community the opportunity to join together as we work towards a Virginia without cancer.

Continuing education credits (CEU) are being offered through VCU Health Continuing Medical Education: 9 AMA credits, 9 ASWB credits, and 9 ANCC credits.

The sponsors of the Virginia Cancer Conference are GRAIL, INOVA Schar Cancer Center, UVA Cancer Center, VCU Massey Cancer Center, Bristol Myers Squibb, SIMA, Virginia Department of Health, Sarah Cannon Cancer Institute/HCA, Centra, and Sentara.

To learn more about the conference and to register, go to the Virginia Cancer Conference website at https://bit.ly/cacv2021.

About CACV: Established in 1998, CACV is a 501(c)(3) organization whose mission and purpose is to facilitate collaborative partnerships among public health agencies, private organizations, cancer centers, other interested agencies and organizations, and individuals and families to carry out recommended cancer control activities. CACV focuses on the prevention, early detection, treatment, advocacy, research, and evaluation of cancer in the Commonwealth of Virginia.

Jessica Deering
Cancer Action Coalition of Virginia
+1 571-499-8314
cacv@cancercoalitionofvirginia.org


Source: EIN Presswire

ValueHealth Hires Penny Lindemann Smith as Chief Financial Officer

Penny Lindemann Smith

Penny Lindemann Smith

Penny Lindemann Smith will manage ValueHealth’s financial performance to support the company’s long-time position as an industry leader and trusted partner.

Penny Lindemann Smith brings deep financial acumen and a passion for excellence to our growing ValueHealth leadership team.”

— ValueHealth CEO, Don Bisbee

KANSAS CITY, MO, UNITED STATES, August 31, 2021 /EINPresswire.com/ — ValueHealth®, LLC, the nationally recognized leader in Ambulatory Centers of Excellence (ACE)™, today announced Penny Lindemann Smith has joined the company’s leadership team as Chief Financial Officer (CFO).

In her role as CFO, Lindemann Smith will manage ValueHealth’s financial performance to support the company’s long-time position as an industry leader and trusted partner. She will focus on leading ValueHealth’s financial organization as well as supporting the execution of the company’s accelerated growth strategy.

“Penny Lindemann Smith brings deep financial acumen and a passion for excellence to our growing ValueHealth leadership team,” says ValueHealth CEO, Don Bisbee. “As a recognized senior executive with an impressive background in corporate business planning and management, she will be instrumental to ValueHealth’s growth and the lasting success in our marketplace.”

Lindemann Smith has more than 20 years of experience in corporate finance and accounting. Prior to joining ValueHealth, she served in a variety of roles for nearly 15 years at NPC International, Inc., a Pizza Hut and Wendy’s franchisee, and the fifth largest U.S. restaurant operator. She most recently served as CFO of NPC’s Wendy’s division where she was responsible for the financial oversight of the Wendy’s business, which approximated 400 restaurants and was the largest Wendy’s franchisee. Lindemann Smith also served as the capital markets and treasury management executive for the consolidated business.

Prior to her career at NPC, Lindemann Smith spent five years as an auditor at KPMG and has been previously licensed as a Certified Public Accountant. Lindemann Smith is a Kansas City native and received her MBA from the University of Kansas and her bachelor’s degree in accounting from Truman State University.

About ValueHealth 

ValueHealth has pioneered the ambulatory surgical space since 1997. Today, the company is leading the country in healthcare's transformation to value-based care, with data-driven protocols that are rapidly positioning its innovative approach as the gold standard for the industry. This data-driven healthcare services company offers a surgical digital platform designed to accelerate the transition from fee-for-service to value-based surgical care model while positioning its provider partners to flourish in an emerging risk environment. Today, ValueHealth operates in more than 30 states, and its nationally recognized Ambulatory Centers of Excellence (ACE)™ are leaders in the transition to value-based care. For more information, visit valuehealth.com. 

Teresa Olsen
ValueHealth, LLC
tolsen@valuehealth.com


Source: EIN Presswire

An Open Letter to the Presidents of Ukraine, Russia and USA from Krishnan Suthanthiran of TeamBest Global Companies

TeamBest Global Companies logo — www.teambest.com

TeamBest Global Companies logo — www.teambest.com

Best Cure Foundation logo — www.bestcure.md

Best Cure Foundation — www.bestcure.md

KITSAULT ENERGY logo — www.kitsaultenergy.com

KITSAULT ENERGY logo — www.kitsaultenergy.com

3E Organization — Promoting Education, Empowerment & Equality (logo)

3E Organization — Promoting Education, Empowerment & Equality (logo)

Krishnan Suthanthiran, President & Founder of TeamBest Global Companies, Best Cure Foundation & Kitsault Energy

Krishnan Suthanthiran, President & Founder of TeamBest Global Companies, Best Cure Foundation & Kitsault Energy

MOSCOW, RUSSIA, August 31, 2021 /EINPresswire.com/ — It is expected that the Honorable President of Ukraine Vladimir Zelenskiy will be meeting with President Joseph Biden of USA today. In view of this, I am writing an 'Open Letter' with a humble request.

I have been to Russia many times up until 2018, as Russian Cancer Centers are using TeamBest Global Companies' Technologies for Cancer Treatment, as are the Cancer Centers in Ukraine and USA. In fact, every Cancer Center needs our technologies, as we manufacture and sell globally the low, medium, high and the highest of high-tech products for Cancer Diagnosis and Treatment.

COVID-19 and its mutations/variants have shown the glaring weaknesses in the Global Healthcare Delivery System. At the current rate, Russia may lose as many as 500,000 citizens; in the USA more than 700,000 citizens from COVID-19 and its variants by the end of this year. Globally, the death toll may be more than 5 million by the end of this year.

Over an 18-month period during this COVID-19 Pandemic, the 500 "ultra rich" have increased their wealth by more than 10 trillion USD, while billions of global citizens became poorer, with hundreds of millions losing their jobs, family members/friends/relatives, some becoming disabled, losing homes, dying of starvation/malnutrition, etc., in addition to the many millions of deaths from COVID-19 itself.

USA and Russia are two great world powers, and their full scientific, technological, financial and diplomatic efforts are needed to resolve many global conflicts. It will be the best of all outcomes to work together to solve and avoid many of the ongoing human tragedies of conflicts (military or otherwise), never-ending bloodshed, and in many ways, wasting our limited valuable resources.

I truly believe that the citizens of all nations would prefer peace, stability and progress towards prosperity — not only in Belarus, Russia, Ukraine, USA, Afghanistan and elsewhere.

I sincerely hope that the meeting between the Presidents of Ukraine and USA this week will pave a pathway for peace and prosperity, not only in all of Ukraine, but Belarus and other neighboring countries.

The world has witnessed the devastations of the Global COVID-19 Pandemic, along with many other natural and man-made disasters. I am hoping and praying that the great powers of Russia and USA will make efforts to pave the way for global peace, prosperity and de-escalation of conflicts.

Honorable President Zelenskiy of Ukraine, we are wishing you a warm welcome to USA! I do hope that I will have an opportunity in the future to work with your government, as well as those of Russia and USA to establish the Best Cure Global Healthcare Delivery System, focusing on the Best Cure Total Health Approach of Prevention, Early Detection and Effective Treatment for Total Cure. The System utilizes a network of Hub-and-Spoke Model Healthcare Delivery Systems, with Express and Mobile Clinics linked to General and Multi-Specialty Medical Centers, connected to 3-6 Star Apartment Hotels.

The focus of this is to reduce death and suffering from Cancer, Cardiac, Diabetes, Obesity, Infectious and all other diseases by 50% or more.

I am look forward to visiting Ukraine and Russia in the near future! Best wishes for a long healthy life to you and your people. Health is wealth!

To read more about Krishnan Suthanthiran, visit his bio page: http://www.teambest.com/about_bio.html
To read most recent news from TeamBest Global Companies, please visit: http://www.teambest.com/news_press.html

Websites to visit:
www.teambest.com
www.bestcure.md
www.kitsaultenergy.com

Related links:
August 23, 2021 Press Release:
https://www.einpresswire.com/article/549547269/open-letter-to-president-xi-jinping-of-china-from-krishnan-suthanthiran-president-founder-of-teambest-global-companies

June 16, 2021 Press Release:
https://www.einpresswire.com/article/543990135/open-letter-to-fellow-citizens-of-the-world-saving-lives-making-quality-education-healthcare-affordable-accessible

May 13, 2021 Press Release:
https://www.einpresswire.com/article/540958501/open-letter-to-honorable-premier-jason-kenney-of-alberta-canada-energy-industry-leaders-from-krishnan-suthanthiran

May 12, 2021 Press Release:
https://www.einpresswire.com/article/540756299/open-letter-to-president-joe-biden-first-lady-dr-jill-biden-to-make-quality-higher-education-affordable-accessible

May 11, 2021 Press Release:
https://www.einpresswire.com/article/540756932/open-letter-to-potus-and-flotus-from-krishnan-suthanthiran

April 13, 2021 Press Release:
https://www.einpresswire.com/article/538534481/teambest-global-companies-to-launch-best-drug-discovery-institute-on-new-1500-acre-corporate-campus-in-virginia-usa

April 12, 2021 Press Release:
https://www.einpresswire.com/article/538487862/teambest-global-a-technology-group-plans-to-establish-new-1500-acre-corporate-campus-in-best-green-city-virginia-usa

December 9, 2020 Press Release:
https://www.einpresswire.com/article/529009371/best-cure-foundation-bcf-teambest-global-tbg-companies-launch-their-global-healthcare-delivery-starting-in-2021

July 6, 2020 Press Release:
https://www.einpresswire.com/article/521083591/correction-an-open-letter-to-the-prime-ministers-of-canada-and-india-from-krishnan-suthanthiran-i-too-have-a-dream

Krishnan Suthanthiran • President & Founder
TeamBest Global • Best Cure Foundation • Kitsault Energy
+1 703-451-2378
email us here


Source: EIN Presswire

Innovative Y-90 SIRT Cancer Treatment Offers Hope to Liver Cancer Patient

Dr. Geschwind in procedure room with his team getting ready to treat a liver cancer with Y-90 Selective Internal Radiation Therapy.  patient

Dr. Jeff Geschwind, Director of Oncology, USA Oncology Centers, and his team get ready to treat a liver cancer patient with Y-90 Selective Internal Radiation Therapy.

Dr. Jeff Geschwind, Director, USA Oncology Centers

USA Oncology Centers Offer Office-Based Procedure in Fight Against Cancer

These state-of-the-art procedures performed under image guidance are extremely precise in their ability to kill liver tumors and are immensely beneficial to patients suffering from liver cancer.”

— Jeff Geschwind, MD, Director of USA Oncology Centers

NORTHBROOK, IL, USA, August 31, 2021 /EINPresswire.com/ — USA Oncology Centers is extremely proud to announce that a patient with Hepatocellular Carcinoma (HCC) was successfully treated with Y-90 Selective Internal Radiation Therapy. This innovative image-guided treatment infuses millions of radioactive (yttrium 90 or Y90) resin microspheres via a tiny catheter that is placed precisely under direct image guidance into the liver. Once in position, the microspheres selectively target liver tumors and deliver a dose of radiation up to 40 times greater than that of conventional external radiotherapy. What is truly remarkable is that this massive dose of radiation spares the healthy liver since the microspheres carrying the radiation are delivered selectively through the artery that exclusively supplies blood to the tumors.

This highly advanced, non-surgical treatment was performed recently on a Danbury, Connecticut woman with Hepatocellular Carcinoma in the background of liver cirrhosis, which is a chronic inflammation of the liver that ultimately can lead to liver cancer. The incidence of primary liver cancer has tripled over the past few decades in the Unites States, primarily due to the rise in hepatitis C viral infection and obesity, which both can cause cirrhosis. After several discussions with the patient’s family and her physicians, the decision was made to proceed with Y-90 Selective Internal Radiation Therapy.  

“This patient was an ideal candidate for Y-90 Selective Internal Radiation Therapy,” said Jeff Geschwind, MD, Director of USA Oncology Centers. “The treatment will prevent the tumors in her liver from growing thereby allowing her to remain eligible for a liver transplant.”

“These state-of-the-art procedures performed under image guidance are extremely precise in their ability to kill liver tumors and are immensely beneficial to patients suffering from liver cancer,” said Geschwind. “And these procedures are perfect for an outpatient setting. Not only do they provide hope for patients with liver cancer, but now such patients no longer need to even go to a hospital to be treated effectively.”

When a patient is diagnosed with primary liver cancer or hepatocellular carcinoma (HCC), the best option for a cure is to undergo a liver transplant. Unfortunately, most patients are not eligible for such a therapy because liver cancer is frequently diagnosed at an advanced stage.

“One way to maximize the chances a patient stays on the transplant list is to treat them while the cancer is still at an early stage to prevent its growth,” said Geschwind. “This is precisely what USA Oncology Centers has performed on this patient.”

Approved by the Food and Drug Administration, Y-90 Selective Internal Radiation Therapy can be used to treat both primary and metastatic liver cancer. These microscopic, radioactive microspheres offer ground-breaking results to control and even eliminate cancers in the liver that cannot be removed with surgery.

This Y-90 Selective Internal Radiation Therapy has given the patient, Vanessa Ananias, new hope and a second chance in a year that included not only her battle with liver cancer, but also a fight with COVID-19. The 49-year-old woman has had a life filled with unexpected health problems. Growing up in Brazil, Ms. Ananias has suffered from kidney stones since her teenage years. In her early 40’s she was diagnosed with diabetes and suffered a mild heart attack. After coming to the United States in 2008, Ms. Ananias still suffered from health problems, although she worked and exercised regularly. Ultimately, kidney stones led to her incidental diagnosis of nonalcoholic fatty liver disease (NAFLD) and, in turn, primary liver cancer or HCC.

“When my mom was finally diagnosed with liver cancer, she was offered no real options,” said Matheus Ananias, who helps his Portuguese-speaking mother navigate the medical system. “Because she is in the process of applying for citizenship and has no insurance, it takes longer for my mom to receive health care. We were utterly hopeless in a world suddenly impacted by the pandemic.” 

“Hope that was taken from us was restored,” her son said. “The procedure was performed the same day, and my mom felt well enough to return to work almost immediately.”

She will now be monitored closely with imaging to ensure her tumors have been effectively treated. If needed, patients can be re-treated to achieve complete tumor destruction or treat possible recurrences. The targeted nature and high level of precision of this therapy enable doctors to deliver more radiation to the liver tumors than would be possible using conventional external beam radiotherapy.

“The patient’s overall cancer care comes first at USA Oncology Centers to provide the best clinical outcomes and patient experience,” said Founder and CEO Yan Katsnelson, M.D. “Our world-class physicians offer the most advanced minimally invasive procedures that are transforming lives and making a real difference in the fight against liver cancer.”

About USA Oncology Centers  

USA Oncology Centers specializes in offering advanced innovative treatments for primary and secondary liver cancer. We provide a holistic approach to treating cancer with minimally invasive procedures that effectively target tumors, require no hospitalization, and improve patients’ quality of life. USA Oncology Centers is part of the USA Clinics Group, a national leader in outpatient care that has grown to include four specialties: USA Vein Clinics, USA Fibroid Centers, USA Vascular Centers, and USA Oncology Centers. For more information, call or visit www.usaoncologycenters.com, or call 855-870-4747.

News Center
USA Oncology Centers
+1 224-433-3291
email us here


Source: EIN Presswire